摘要
目的 评价紫杉醇联合顺铂治疗晚期非小细胞肺癌的疗效。方法 全组90例,应用紫杉醇135mg/m^2,静脉3h输注,顺铂75mg/m^2静脉输注。每3周为1周期,进行3个周期。结果 90例患者总有效率55.6％。初治患者58例,有效率62.1％;复治患者32例,有效率43.8％(P<0.05)。ⅢB期有效率65.5％(38/58);Ⅳ期有效率37.5％(12/32)。统计学处理X^2=6.56,P<0.01。主要毒副作用是骨髓抑制、肌肉、关节酸痛、食欲下降、恶心、呕吐,但均可耐受。结论 紫杉醇联合顺铂是治疗非小细胞肺癌的有效药物,对某些复治病例仍有一定疗效。骨髓抑制是主要的副作用,应用集落刺激因子可以改善骨髓抑制程度。
Objective To evaluate the results of combination chemotherapy with paclitaxel(TAX) and cispktin (PDD) in patients with advanced non-small cell lung cancer(NSCLC). Methods 90 cases of advanced NSCLC were treated with TP regimen in this study. Paclita-xel(TAX) 135mg/m2, d1, and cispktin (PDD)75mg/m2, d1,d2. A cycle was 3 weeks and each patient had been continued 3 cycles. The effect and side-effects were observed on each patient. Results Response rate (RR) was observed in 55.6% of 90 patients, first 58 cases RR was 62.1%, recurrent 32 cases RR was 43.8%(P< 0.05); ⅢB stage patients RR was 65.5%, Ⅲ stage patients RR was 37.5% (P<0.01). The main side-effect was myelosuppression and muscle-arthrodynia. Conclusion. The results indicated that chemotherapy with TP regimen is safe and effective for patients and side-effects are endurable by patients.
出处
《实用肿瘤学杂志》
CAS
2003年第4期272-274,共3页
Practical Oncology Journal
